NEEDLE-FREE JET INJECTION BIBLIOGRAPHY, DEVICE & MANUFACTURER ROSTER, and PATENT LIST
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Incremental Costs of Introducing Jet Injection Technology for Delivery of Routine Childhood Vaccinations: Comparative Analysis from Brazil, India, and South Africa
Vaccine 29 (2011) 969–975 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: Comparative analysis from Brazil, India, and South Africa Ulla K. Griffiths a,∗, Andreia C. Santos a, Neeti Nundy b, Erica Jacoby b, Dipika Matthias b a London School of Hygiene and Tropical Medicine, Tavistock Place, London WC1H 9SH, UK b PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA article info abstract Article history: Background: Disposable-syringe jet injectors (DSJIs) have the potential to deliver vaccines safely and Received 14 May 2010 affordably to millions of children around the world. We estimated the incremental costs of transitioning Received in revised form 9 November 2010 from needles and syringes to delivering childhood vaccines with DSJIs in Brazil, India, and South Africa. Accepted 15 November 2010 Methods: Two scenarios were assessed: (1) DSJI delivery of all vaccines at current dose and depth; (2) a Available online 27 November 2010 change to intradermal (ID) delivery with DSJIs for hepatitis B and yellow fever vaccines, while the other vaccines are delivered by DSJIs at current dose and depth. The main advantage of ID delivery is that only Keywords: a small fraction of the standard dose may be needed to obtain an immune response similar to that of Vaccine Jet injector subcutaneous or intramuscular injection. Cost categories included were vaccines, injection equipment, Costs waste management, and vaccine transport. Some delivery cost items, such as training and personnel Brazil were excluded as were treatment cost savings caused by a reduction in diseases transmitted due to India unsafe injections. -
For Nexplanon® Insertion and Removal G
Wilson et al. Contraception and Reproductive Medicine (2020) 5:1 Contraception and https://doi.org/10.1186/s40834-020-00104-x Reproductive Medicine RESEARCH Open Access Comparison of traditional anesthesia method and jet injector anesthesia method (MadaJet XL®) for Nexplanon® insertion and removal G. Anthony Wilson* , Julie W. Jeter, William S. Dabbs, Amy Barger Stevens, Robert E. Heidel and Shaunta’ M. Chamberlin Abstract Background: This study compared a needle-free anesthesia method with traditional local anesthesia for insertion and removal of Nexplanon® long-acting removable contraceptive device. In our clinic, patients often avoid this highly effective form of contraception due to fear of needles. We sought to determine if patients perceived a difference in pain with the injection, anxiety level or pain with the procedure when local anesthesia was given with a needle v/s a needle-free jet injector device. Methods: Patients were randomly assigned to one of two groups: jet injector or needle lidocaine delivery. Outcomes were ease of use, patient anxiety level, painfulness, and efficacy of anesthesia method. Results: Patient pain perception with administration of jet injector lidocaine was statistically lower than traditional needle with no difference in anxiety or ease of use, or efficacy of the anesthesia. Conclusion: The jet injector device is a reasonable alternative to needle injection delivery of anesthesia prior to insertion/removal of Nexplanon® device. Further studies may determine whether this needle-free alternative for administration of local anesthetic would result in more women choosing Nexplanon® as a contraceptive method. Keywords: Local anesthetic, Nexplanon®, Patient anxiety Background injection of lidocaine differed between the methods of As with many procedures [1, 2], patients often cite a fear delivery, and whether the presence or absence of needles of needles as a major reason to decline Nexplanon® in the anesthesia method affected patient anxiety level. -
Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products
Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products Additional copies are available from: Office of Combination Products Office of Special Medical Programs Office of the Commissioner Food and Drug Administration 10903 New Hampshire Avenue, WO-32 Hub 5129 Silver Spring, MD 20993 (Tel) 301-796-8930 (Fax) 301-796-8619 http://www.fda.gov/CombinationProducts/default.htm This document finalizes the draft guidance issued in April 2009. For questions regarding this document, contact the Office of Combination Products at [email protected] or Patricia Y. Love, MD at 301-796-8933 or [email protected] U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health, Center for Drug Evaluation Research, Center for Biologics Evaluation and Research, and Office of Combination Products in the Office of the Commissioner June 2013 Contains Nonbinding Recommendations Table of Contents INTRODUCTION.....................................................................................................................3 BACKGROUND .......................................................................................................................4 SECTION I: SCIENTIFIC AND TECHNICAL CONSIDERATIONS.............................5 A. INJECTOR DESCRIPTION .............................................................................................5 B. DESIGN FEATURES.........................................................................................................9 -
Growth Hormone Treatment Without a Needle Using the Preci-Jet 50
Archives of Disease in Childhood 1997;76:65–67 65 Growth hormone treatment without a needle Arch Dis Child: first published as 10.1136/adc.76.1.65 on 1 January 1997. Downloaded from using the Preci-Jet 50 transjector P Bareille, M MacSwiney, A Albanese, C De Vile, R Stanhope Abstract Patients and methods A new delivery system (Preci-Jet 50) Twenty eight patients (11 girls, 17 boys) were which administers growth hormone randomly selected from the endocrine clinic at through the skin using high pressure and Great Ormond Street Hospital for Children. without a needle was evaluated. This All patients were receiving growth hormone device was inconvenient and painful com- treatment, 19 through an autoinjector and nine pared with a pen injection system. The with needles and syringes. None was using a conclusion is that the Preci-Jet is not the pen injector system at that time but nine had used one previously. The exclusion criteria panacea for solving the problem of com- were bleeding disorders and diseases of colla- pliance with subcutaneous growth hor- gen synthesis. Mean age was 10.1 (range mone injections. 5.7–16.7) years. The growth hormone dose ( 1997;76:65–67) Arch Dis Child range was from 15 to 30 IU/m2 body surface area/week. The subjects were randomly subdi- Keywords: growth hormone treatment; transcutaneous high pressure administration (jet); needle phobia. vided into two groups, A and B. Sex distribu- tion was similar in both groups but mean age diVered, with values of 8.7 and 11.2 years in groups A and B respectively. -
Dosage Form Description CODE
Dosage Form Description CODE DOSAGE_FORM DOSAGE_FORM DESCRIPTION AERO Aerosol AEPB Aerosol Powder, Breath Activated AERB Aerosol, Breath Activated AERP Aerosol, Powder AERS Aerosol, Solution AUIJ Auto-injector AJKT Auto-injector Kit BAR Bar BEAD Beads CAPS Capsule CAPA Capsule Abuse- Deterrent CPCW Capsule Chewable CPDR Capsule Delayed Release CPEP Capsule Delayed Release Particles CSDR Capsule Delayed Release Sprinkle CDPK Capsule Delayed Release Thereapy Pack C12A Capsule ER 12 Hour Abuse-Deterrent CS12 Capsule ER 12 Hour Sprinkle C2PK Capsule ER 12 Hour Therapy Pack C24A Capsule ER 24 Hour Abuse-Deterrent CS24 Capsule ER 24 Hour Sprinkle C4PK Capsule ER 24 Hour Therapy Pack CP12 Capsule Extended Release 12 Hour CP24 Capsule Extended Release 24 Hour CPEA Capsule Extended Release Abuse-Deterrent CSER Capsule Extended Release Sprinkle CEPK Capsule Extended Release Therapy Pack CPCR Capsule Extended Release* CPSP Capsule Sprinkle CPPK Capsule Therapy Pack CART Cartridge CTKT Cartridge Kit CONC Concentrate CREA Cream CRYS Crystals DEVI Device TEST Diagnostic Test DPRH Diaphragm DISK Disk ELIX Elixir EMUL Emulsion ENEM Enema EXHA Exhaler EXHL Exhaler Liquid Dosage Form Description CODE DOSAGE_FORM DOSAGE_FORM DESCRIPTION EXHP Exhaler Powder EXHS Exhaler Solution EXHU Exhaler Suspension FILM Film FLAK Flakes EXTR Fluid Extract FOAM Foam GAS Gas GEL Gel SOLG Gel Forming Solution GRAN Granules GREF Granules Effervescent GUM Gum IMPL Implant INHA Inhaler INJ Injectable INST Insert IUD Intrauterine Device JTAJ Jet-injector (Needleless) JTKT Jet-injector -
Cold and Flu Season
The DrugSmith is The Monthly Newsletter of The Smith Drug Company A Division of J M Smith Corporation Spartanburg, SC • Paragould, AR • Valdosta, GA Cold and Flu Season National Flu Vaccination Week World AIDS Month Introducing: Inject-Safe™ Barrier Bandage The first and only bandage designed specifically for injections. • Improved Safety Relieving Symptoms of the Common Cold 4 • Lower Cost National Influenza Vaccination Week 2016 6 • More Convenient • Less Pain What's New With The Flu? 7 Why Get A Flu Shot? 9 HealthWise Connect: Coming Soon! 11 World AIDS Day 12 Colon Rectal Cancer: Basic Facts 16 Healthwise™ Clinical Solutions Healthwise™ Circular Program DollarWise™ Program Good Sense® Controlled Label Program Greeting Cards Program Continuing Education Gift and Trade Show ™ Benefits of the Inject-Safe™ Barrier Bandage Rx QuickShip Third Party Station Inject-Safe™ Barrier Bandages self-seal to help contain Pharmacy First bleeding following an injection. DrugSmith™ Monthly Newsletter Consistent with “Universal Precautions” established by Smith Weekly e-Blast OSHA. Diabeticare Program Hamacher Retail Zone Pricing Protects the healthcare provider from coming into contact with potential blood borne pathogens. Home Health Care Catalog HealthWise Signage Program Allows healthcare provider to use both hands to dispose of Smith Gift Box Gift Category the needle. Vials and Vitamin Program Meets OSHA Blood borne Pathogen Standard's definition Direct Mail Advertising of "Engineering Control," for use to reduce employee Well Staffed Customer Service -
Maxillo, Pain EYE & ENT DNB Q & A
Dr. Azam’s Notes in Anesthesiology Postgraduates appearing 3rd Edition for MD, DNB & DA Exams Maxfax, Pain, Eye, ENT & Orthopedic Edited by: Dr. Azam Consultant Anesthesiologist & Critical Care Specialist www.drazam.com 2 Dr Azam’s Notes in Anesthesiology 2013 Dedication To Mohammed Shafiulla, my father, my oxygen, companion, and best friend; for being my major pillar of support and making this vision a reality. Thank you for your continual sacrifices with boundless love and limitless gratitude, for the sake of your children. I owe you a debt I can never repay. I also would like to thank my mom (Naaz Shafi), my wife (Roohi Azam), my two lovely kids (Falaq Zohaa & Mohammed Izaan), for their support, ideas, patience, and encouragement during the many hours of writing this book. Finally, I would like to thank my teachers (Dr.Manjunath Jajoor & team) & Dr T. A. Patil . The dream begins with a teacher who believes in you, who tugs and pushes and leads you to the next plateau, sometimes poking you with a sharp stick called "truth." 3 Dr Azam’s Notes in Anesthesiology 2013 Dr Azam’s Notes in Anesthesiology 2013 A NOTE TO THE READER Anesthesiology is an ever-changing field. Standard safety precautions must be followed, but as new research and clinical experience broaden our knowledge, changes in treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current product information provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administration, and contraindications. -
Unit 4: Medication Administration Fundamental of Nursing
Unit 4: Medication Administration Fundamental of Nursing Unit 4: Medication Administration: Medication: Is a substance administered for the diagnosis, cure, treatment, relief, or prevention of disease. Six Rights of Medication Administration After paramedics have received the medication or fluid order, they should then administer the drug in question. In performing drug administration, pre-hospital care providers adhere to the six rights of medication administration: 1. Right patient 2. Right medication 3. Right dose 4. Right route 5. Right time 6. Right documentation Basic principle of nurse on drugs administration 1. The nurse must know the drug's prescribed dose, method of administration, actions, expected therapeutic effect, possible interactions with other drugs, and adverse effects. 2. The nurse must know the institution's administration procedures for the client's welfare and the nurse's legal protection. 3. The nurse must Review physician's order for completeness the client's name, date of the order, name of the drug, dose, rout, time of administration, and the physician's signature. 1 Unit 4: Medication Administration Fundamental of Nursing 4. The nurse discusses the medication and its actions with the client; recheck the medication order if the client disagrees with the dose or the physician's order. 5. The nurse must check the physician's order against the client's medication administration record for accuracy. 6. The nurse gives the patient the right to know about the medication he is receiving and the right to refuse it. Routes of Administration A: Enteral Tract Routes The common enteral routes of administration used in general medical practice are as follows: 1. -
• the PDL Is a List of Over 100 Therapeutic Classes Reviewed by the Pharmaceutical & Therapeutics (P&T) Committee
Louisiana Medicaid Preferred Drug List (PDL)/Non-Preferred Drug List (NPDL) http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf • The PDL is a list of over 100 therapeutic classes reviewed by the Pharmaceutical & Therapeutics (P&T) committee. In addition, there are medications and/or classes of medications that are not reviewed by the committee. Unless there is a clinical pre-authorization requirement for the entire class (as noted on the last page of the PDL) these medications will continue to be covered without prior authorization. Examples: spironolactone, hydrochlorothiazide, amoxicillin suspension • There is a mandatory generic substitution unless the brand is preferred and the generic is non-preferred. When the brand is preferred and the generic is non-preferred, no special notations are required by the prescriber and the pharmacist enters “9” in the DAW field 408-D8. • When the brand is non-preferred and the prescriber has determined it to be medically necessary, “Brand medically necessary” or “Brand necessary” must be written on the prescription in the prescriber’s handwriting or via an electronic prescription and the pharmacist enters “1” in the DAW field 408-D8. For more information, please refer to the following policy: https://www.lamedicaid.com/provweb1/Providermanuals/manuals/PHARMACY/PHARMACY.pdf • To locate any medication on this list, you may use the keyboard shortcut CTRL + F to search. • New medications that enter the marketplace in classes reviewed by P&T committee will be considered non-preferred requiring prior authorization until the next P&T committee meeting. Please refer to the following criteria: New Drugs Introduced into the Market / Non-Preferred • The PDL is arranged by therapeutic class with an item number and may contain a subset of medications under each therapeutic class. -